Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Novo Nordisk inked an obesity deal worth up to $2.2 billion on Wednesday, and sent shares of Septerna into the stratosphere.

CVS Health CVS shares have rallied nearly 38% so far this month, driven by the company’s stronger-than-expected first-quarter ...

Dow Jones Top Company Headlines at 9 PM ET: UnitedHealth Group Is Under Criminal Investigation for Medicare Fraud | Dick’s ... UnitedHealth Group Is Under Criminal Investigation for Medicare Fraud ...

Dow Jones Top Company Headlines at 7 PM ET: Cisco Systems Boosts Outlook After Posting Higher Profit, Sales | Dick’s ... Cisco Systems Boosts Outlook After Posting Higher Profit, Sales The ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...